title: Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.
abstract: The current study was designed to evaluate the toxicity and activity of Spartaject Busulfan, a microcrystalline preparation of busulfan, following its intrathecal administration into a nude rat model of human neoplastic meningitis. Animals were treated through permanent indwelling subarachnoid catheters. Human glioma D-456 MG growing in the subarachnoid space was treated with 8.1 micromol of intrathecal Spartaject Busulfan. Single-dose therapy was also subsequently compared with 4 doses of 8.1 and 2.0 micromol busulfan, respectively, against D-456 MG neoplastic meningitis. Additional experiments evaluated a saline control versus 8.1 micromol x 1, 6.2 micromol x 4 and 4.1 micromol x 4, respectively, against D-456 MG. A single dose of 8.1 micromol of intrathecal Spartaject Busulfan resulted in an increase in median survival of 61.7% compared with the saline control. In experiment 2, all busulfan treatments showed increases in median survival of 142.8% (8.1 micromol x 1), 52.3% (2.0 micromol x 4), and 23% (8.1 micromol x 4) (p < 0.001 for all groups) compared with the saline control. These results suggest that a narrow therapeutic dose range for both toxicity and activity has been defined for intrathecal busulfan in the treatment of human neoplastic meningitis in athymic nude rats. Although busulfan has only limited activity against solid tumors, the high doses achievable in the CSF following intrathecal administration coupled with the steep dose-response relationships of alkylating agents, provide rationale for further evaluation of this agent.
authors.affiliation: Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: G E
authors.initials: GE
authors.lastname: Archer
authors.forename: J H
authors.initials: JH
authors.lastname: Sampson
authors.forename: R E
authors.initials: RE
authors.lastname: McLendon
authors.forename: A H
authors.initials: AH
authors.lastname: Friedman
authors.forename: O M
authors.initials: OM
authors.lastname: Colvin
authors.forename: M
authors.initials: M
authors.lastname: Rose
authors.forename: H
authors.initials: H
authors.lastname: Sands
authors.forename: W
authors.initials: W
authors.lastname: McCullough
authors.forename: H E
authors.initials: HE
authors.lastname: Fuchs
authors.forename: D D
authors.initials: DD
authors.lastname: Bigner
authors.forename: H S
authors.initials: HS
authors.lastname: Friedman
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005909:Glioblastoma / Q000150:complications* / Q000188:drug therapy*; D007278:Injections, Spinal; D008577:Meningeal Neoplasms / Q000150:complications* / Q000188:drug therapy*; D008581:Meningitis / Q000209:etiology*; D051381:Rats; D011923:Rats, Nude; D013346:Subarachnoid Space; D016019:Survival Analysis
chemical_list: D018906:Antineoplastic Agents, Alkylating; D002066:Busulfan